Efficacy and Safety of Paclitaxel-Coated Balloon Catheter in Patients With Long De Novo Lesions of Main Coronary Arteries
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stable Angina Pectoris
- Sponsor
- The People's Hospital of Liaoning Province
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- QCA late lumen loss
- Last Updated
- 8 years ago
Overview
Brief Summary
This study evaluates the Efficacy and Safety of Paclitaxel-Coated Balloon Catheter in Patients With Diffuse Long De Novo Lesions of Main Coronary Arteries.
Detailed Description
Paclitaxel-Coated Balloon Catheter is a new device in coronary disease, it can inhibit the proliferation of smooth muscle of coronary vessels by transitory contaction, without residual implantation. More and more evidences have shown its efficacy and safety in diffuse small coronary disease, bifurcation disease and in-stent restenosis. But there are still seldom evidences in De Novo Lesions of Main Coronary Arteries. PCB has used in some subgroup of many study but confused with in-stent renstenosis or small coronary disease. The investigators designed this study to evaluate the Efficacy and Safety of Paclitaxel-Coated Balloon Catheter in Patients With Diffuse Long De Novo Lesions of Main Coronary Arteries.
Investigators
Zhilin Miao
Vice-Director of Department of Cardiology
The People's Hospital of Liaoning Province
Eligibility Criteria
Inclusion Criteria
- •a diagnosis of stable angina or unstable angina in hospitalized patients. Objective clinical evidence of ischemia (ECT, Exercise ECG, ECG ST-T changes) With CAG proven one vessel lesion（a lesion length of ≥ 20mm)；
- •a lesion diameter stenosis \>75% as evaluated by QCA with a reference diameter of ≥ 2.75 mm and ≤ 3.5 mm .
- •a willingness or ability to provide informed consent，a willingness to receive telephone followed-up at postoperative 1 month, 3 month, 6 month, and an angiographic follow up at postoperative 9 month.
- •a willingness to receive DCB angioplast or DES implantation.
Exclusion Criteria
- •Patients with acute myocardial infarction within 30 days；
- •a previous history of severe valvular heart disease,severe hepatic and renal insufficiency；severe cardiac dysfunction with EF≤40%；
- •advanced cancer with a life expectancy of \<12 months；
- •Patients with abnormal coagulation function, Contraindications for antiplatelet drugs or unable to tolerate antiplatelet therapy;
- •Pregnant and lactating patients；
- •Multiple vessels involvement or multiple lesions requiring intervention treatment,left main artery lesions and coronary artery bypass graft lesions；
- •Stent restenosis
- •Thrombotic disease，severe calcified lesions（Judged by the operator， CAG showed class 2 or more severe calcified lesions），spontaneous dissection or ulcerative lesion，coronary ostial lesions (the lesion included should be an interval of greater than 3mm from the ostial of RCA or LAD)， severe angulated lesions（\>45°）
- •diameter of collateral vessel≥ 2.25 mm requiring interventional therapy,type 1 coronary lesions（Patients with diameter of collateral vessel\< 2.25 mm， who were not treated with DCB dilatation were also eligible）.
Outcomes
Primary Outcomes
QCA late lumen loss
Time Frame: Immediately after the procedure and at 9 months follow-up
minimal lumen diameter at post-procedure minus minimal lumen diameter at 9 months follow-up measured by QCA(quantitative coronary angiography)